Marc Lajoie

Marc Lajoie is a Canadian biochemist and entrepreneur. Marc is the co-founder of GRO Biosciences, a company that develops technologies for safer and more efficacious adoptive T cell therapies.

Lajoie did their undergraduate studies at the University of Toronto before moving to Harvard Medical School to pursue their PhD under the supervision of George M. Church. Their graduate work focused on developing de novo designed protein switches capable of performing Boolean logic for ultra-specific cell targeting, as well as protein assemblies that package their own genomes and evolve useful properties for targeted delivery of biologics.

After completing their PhD, Lajoie stayed on at Harvard as a postdoctoral fellow, first with the Washington Research Foundation and then with the Cancer Research Institute. It was during this time that they and their future business partner, Taylor Crouch, developed the idea for GRO Biosciences.

In 2019, Lajoie left academia to focus full-time on building GRO Biosciences. The company has since raised over $50 million in funding and is currently working on clinical trials for their first product.

Marc Lajoie completed their Ph.D in Chemical Biology at Harvard University and their BA in Biophysical Chemistry at Dartmouth College.